Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria
Myrna
M
Division de Investigación Clínica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Herrera
Aquileo
A
Labardini
Juan
J
González-Fierro
Aurora
A
Trejo-Becerril
Catalina
C
Taja-Chayeb
Lucía
L
Pérez-Cárdenas
Enrique
E
de la Cruz-Hernández
Erick
E
Arias-Bofill
Daymi
D
Vidal
Silvia
S
Cervera
Eduardo
E
Dueñas-Gonzalez
Alfonso
A